Guardant360^® assay can be an alternative to standard of care tissue biopsy with a higher sample success rate¹

Patients enrolled with Guardant360^® achieved similar clinical outcomes as patients enrolled with tissue testing¹

• The objective response rate (ORR) for patients enrolled by plasma or by tissue-based testing and treated with targeted therapy was 20% versus 16.7%, respectively.

• The median progression-free survival (PFS) for patients enrolled by plasma or by tissue-based testing and treated with targeted therapy was 2.4 months versus 2.8 months, respectively.

Reference:
1. Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020 Dec;26(12):1859-1864. doi: 10.1038/s41591-020-1063-5